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OBJECTIVES This study was designed to determine the effect of coronary stents on in-hospital mortality.
BACKGROUND Despite extensive use of stents for percutaneous coronary interventions (PCIs), their effect on
serious in-hospital events, especially mortality, is not well defined.
METHODS A cohort study was performed using 16,811 consecutive native-vessel PCI procedures
performed on patients in the Society for Cardiac Angiography & Interventions Registry from
July 1, 1996, through December 31, 1998. Patients undergoing balloon-only angioplasty were
compared with those receiving a planned or unplanned stent. Procedures with other devices
were excluded. Multivariable analyses adjusted for detailed clinical characteristics and for
individual laboratory.
RESULTS Stents were associated with a significant reduction in in-hospital mortality (0.3%) compared
with balloon procedures (0.6%; multivariable odds ratio [OR] 0.55; 95% confidence interval
[CI] 0.34, 0.89; p 5 0.014). The risk of emergency coronary bypass also was reduced by
stenting (0.3% vs. 0.7%; multivariable OR 0.47; 95% CI: 0.29, 0.76; p 5 0.002). Adjustment
for the use of glycoprotein IIb/IIIa inhibitors did not change the results, and the effects of
stenting relative to balloon procedures were similar in those procedures with and without
glycoprotein IIb/IIIa blockade (p 5 0.94).
CONCLUSIONS This study suggests that coronary stenting, compared with balloon procedures, reduces
in-hospital mortality, independent of the clinical setting. (J Am Coll Cardiol 2001;37:
499–504) © 2001 by the American College of Cardiology
Despite the explosive growth in the use of coronary artery
stenting for percutaneous coronary interventions (PCIs) (1),
primarily justified by the reduction in restenosis demon-
strated in randomized trials (2–7), few data have been
available from routine clinical practice to determine the
effects of stents on in-hospital events, especially mortality
(8). Although randomized trials of coronary stents have not
been specifically designed to examine in-hospital mortality
(3–7,9), several trials, in the absence of adjuvant platelet
glycoprotein IIb/IIIa (GP IIb/IIIa) receptor blockade, have
shown a nonsignificant excess of cardiac events in patients
receiving coronary stents (1,3,4,6). In contrast, a recent
study using administrative data raised the possibility that
stents reduce in-hospital mortality (8). Randomized trial
data comparing stents plus abciximab with balloon angio-
plasty plus abciximab also demonstrated a reduction in
six-month rates of death with stenting (10). However, the
contribution of periprocedural mortality to these six-month
findings is not known, nor are the effects of stenting versus
balloon procedures independent of adjuvant therapies.
Equally important, the effect of coronary stenting on mor-
tality in broad-based practice may differ from the results of
randomized trials that often include only carefully selected
patients and experienced practitioners.
If stents do reduce mortality in actual practice, then
further expansion of their use and reassessment of bench-
mark standards of short-term PCI outcomes should be
employed. It is therefore critical for the cardiovascular
community to clarify the effects of stenting on mortality in
actual practice. The specific aims of this study were to
examine the effects of coronary stenting in broad-based
clinical practice on in-hospital mortality and the interaction
of these effects with the use of GP IIb/IIIa inhibitors and
with other clinically important groups of patients.
METHODS
Data source. This study included consecutive patients
undergoing PCI from July 1, 1996, through December 31,
1998, in the SCA&I Registry. Details of the SCA&I
Registry data collection techniques and variable definitions
have been reported previously (11,12). Briefly, detailed
clinical characteristics of all patients undergoing PCI were
entered into the Registry by support personnel in each
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laboratory prior to each patient’s procedure, and all in-
laboratory outcomes and in-hospital deaths were recorded
after the procedure. The data entry program included range
and logic checks to prevent incorrect keying of data.
Patient population and laboratories. A total of 19,510
angioplasty procedures were performed in 33 centers par-
ticipating in the SCA&I Registry. Fifteen centers contrib-
uted data to all 21⁄2 years of the Registry. Procedures
involving devices other than balloons or stents were ex-
cluded (1,354 procedures; mortality 0.5%, p 5 0.7 com-
pared with included patients).
The indications for stenting were prospectively defined
and these definitions were used by all centers in the
Registry. “Planned” stenting (n 5 8,410) was defined as the
intended use of a stent prior to beginning a procedure,
whereas “unplanned” stents (n 5 2,280) were those used
after a balloon inflation because of unsatisfactory balloon
results, including minor dissection. If a stent was used to
treat the acute complication of either abrupt artery closure
or impending closure following an initial procedure (regard-
less of the initial device used) it was considered to be a
“bailout” procedure. These procedures did not use stents
simply to improve the angiographic appearance of balloon
angioplasty or to treat minor dissection.
The purpose of this study was to examine the effects of
stents when used as planned therapy. However, because
unplanned stents could be used to improve the angiographic
appearance of a balloon angioplasty, they were considered
part of “routine” PCI practice, and were therefore included
in the study population. Secondary analyses excluded them.
Few stents were coded as “bailout” (n 5 150, 1.2% of all
procedures), reflecting the low incidence of major compli-
cations in this study; the majority (69%) were used to treat
complications of balloon angioplasty (n 5 104). However,
abrupt vessel closure is itself a complication of angioplasty
(13–15) and bailout stents are used to treat these compli-
cations. Therefore, it would be inappropriate to include
bailout stents as predictors of the acute complications
studied (16). It should be noted, however, that including
procedures requiring bailout stenting did not change the
study results.
Because PCI of coronary bypass grafts represents a
different type of procedure and because of the limited
number of graft procedures (330 balloon procedures with no
mortality and 811 stent procedures with only two deaths),
graft PCI procedures also were, a priori, excluded. The
study population therefore consisted of subjects undergoing
either isolated balloon angioplasty or stenting, planned or
unplanned, of native coronary vessels.
Study variables. The primary outcome variable was mor-
tality, defined as death occurring any time during the
hospitalization. Cause of death was not recorded. In addi-
tion, we examined emergency coronary artery bypass graft-
ing (CABG), defined as CABG required immediately
following the PCI procedure. This was further divided into
“unstable” CABG (patients going to CABG with ongoing
ischemia and/or hemodynamic instability) and “stabilized”
CABG (patients going to CABG without ischemia or
hemodynamic instability). Because of the lack of standard-
ization of surveillance for myocardial infarction (MI), this
outcome was not included.
Data on the type of device and indication for stenting
(planned vs. unplanned) were available for 100% of proce-
dures. Data were complete for mortality and CABG out-
comes for 99.7% of procedures. Complete data also were
available for .95% of all other study variables.
Analyses. The demographic characteristics of subjects un-
dergoing stent versus balloon procedures were compared
using chi-square statistics. The unadjusted associations
between stent use and the outcomes were estimated using
odds ratios (ORs) and chi-square statistics.
To control for confounding by individual patient-level
factors and also for the potential for confounding by
laboratory (17,18) (because of enormous variation in the
rates of use of stents across the participating hospitals), a
two-stage procedure was used. First, a propensity score
model was derived to predict the use of stents across
hospitals (19,20). Propensity scores reduce the potential for
selection bias and allow for simultaneous adjustment for
multiple confounders without resulting in model overfitting
(as would occur if each laboratory were included in a
multivariable regression model) (19). In this initial model,
the outcome was stent (vs. balloon procedures) and the
predictors included laboratory, year, age, gender, heart
failure, renal insufficiency, diabetes, hypertension, multives-
sel disease, peripheral vascular disease, unstable angina,
American Heart Association/American College of Cardiol-
ogy lesion type, MI prior to procedure, shock (systolic blood
pressure ,80 mm Hg and cardiac index ,1.8 l/min/m2
despite, or requiring, pharmacological or mechanical sup-
port), use of platelet GP IIb/IIIa blockers, use of thrombo-
lytics, emergency and ad hoc procedures and prior CABG
and PCI. Multi- versus single-vessel PCI was not included
because unsatisfactory results of the first balloon dilation of
a planned multivessel procedure could lead to the use of
unplanned stenting and aborting further lesion dilations.
This would make single-vessel PCI appear to predict stent
use when, in fact, the need for the stent was the reason for
performing only a single-vessel PCI. Vessel size was not
included because: 1) it was not associated with mortality
(p 5 0.5); 2) it was missing in 30% of subjects; and 3)
adjustment for vessel size in the subset of patients with
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CI 5 confidence interval
MI 5 myocardial infarction
OR 5 odds ratio
PCI 5 percutaneous coronary intervention
SCA&I 5 Society for Cardiac Angiography and
Interventions
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known vessel size did not alter the findings (i.e., vessel size
was not a confounder). The Hosmer–Lemeshow goodness-
of-fit statistic (21) was used to assess the fit of the logistic
model.
In the second stage, the patients were grouped into
deciles of propensity to receive a stent based on the initial
model. These deciles were then used as an indicator variable
in logistic regression models that included only the propen-
sity score and the device variable as independent variables.
This method allows for determination of the effect of stents
after adjustment for all variables included in the original
propensity score model discussed earlier (19,20).
Interactions between device type and other risk factors
were examined using multivariable logistic regression with
the appropriate interaction terms, a propensity score that
was derived using hospital only, and all other potential
confounders. The a priori interaction subgroups were age,
diabetes, use of GP IIb/IIIa inhibitors, MI within 24 h prior
to PCI and lesion type.
Because outcomes may be correlated within laboratories
(i.e., there is a potential lack of independence of the risk of
outcomes within centers) (17), all analyses accounted for
clustering of patients within laboratories using robust vari-
ance estimates (22). Analyses were performed using SPSS
version 9.0.1 (SPSS Incorporated, Chicago, Illinois) and
Stata version 5 (Stata Corporation, College Station, Texas).
RESULTS
Study population and predictors of stent use. A total of
16,811 procedures were performed among 33 laboratories.
There were 6,121 balloon-only and 10,690 stent procedures.
The demographics of the population are shown in Table
1. Patients undergoing a balloon procedure were more likely
to be female, undergo PCI within 24 h of an MI or as an
emergency procedure, and have diabetes, renal insufficiency,
multivessel disease, prior CABG, prior PCI and shock.
Stent patients, however, were more likely to undergo an
Table 1. Characteristics of Population by Device Type*
Clinical Characteristic
Procedure
p Value
Balloon Only
(n 5 6,121)
Stent
(Planned or
Unplanned)
(n 5 10,690)
Age $65 2,665 (43.5%) 4,464 (41.8%) 0.25
Congestive heart failure 249 (4.1%) 483 (4.5%) 0.17
Diabetes mellitus 1,389 (22.7%) 2,120 (19.8%) , 0.001
Emergency procedure† , 0.001
Elective 4,590 (75.4%) 7,756 (73.0%)
Urgent 444 (7.3%) 1,474 (13.9%)
Emergency 1,054 (17.3%) 1,398 (13.2%)
Female gender 2,219 (36.3%) 3,467 (32.4%) , 0.001
Hypertension 3,089 (50.5%) 5,269 (49.3%) 0.14
Glycoprotein IIb/IIIa receptor blocker 678 (11.1%) 1,499 (14.0%) , 0.001
MI within 24 h before PCI 668 (11.4%) 840 (8.2%) , 0.001
MI 2–7 days before PCI 639 (10.9%) 1,415 (13.8%) , 0.001
MI 8–30 days before PCI 85 (1.4%) 190 (1.9%) 0.051
Multivessel disease 2,820 (46.3%) 4,615 (43.3%) , 0.001
PCI done during diagnostic procedure 3,377 (55.2%) 5,735 (53.6%) 0.057
Peripheral vascular disease 288 (4.7%) 510 (4.8%) 0.85
Prior CABG 738 (12.1%) 1,057 (9.9%) , 0.001
Prior thrombolytic therapy 257 (4.2%) 604 (5.7%) , 0.001
Prior PCI 1,896 (31.0%) 2,478 (23.2%) , 0.001
Renal insufficiency 137 (2.2%) 183 (1.7%) 0.016
Shock 129 (2.1%) 152 (1.4%) 0.001
Unstable angina 3,646 (59.6%) 7,070 (66.1%) , 0.001
Worst lesion type attempted‡ , 0.001
Type A 1,211 (20.0%) 1,704 (16.3%)
Type B 3,883 (64.3%) 7,040 (67.2%)
Type C 948 (15.7%) 1,733 (16.5%)
Year§ , 0.001
1996 1,213 (56.3%) 941 (43.7%)
1997 2,573 (41.5%) 3,630 (58.5%)
1998 2,335 (27.6%) 6,119 (72.4%)
*CABG 5 coronary artery bypass graft surgery; MI 5 myocardial infarction; n 5 number; PCI 5 percutaneous coronary
intervention; †“Urgent” procedure is one that is required within 24 h to minimize chance of further clinical deterioration;
“emergency” requires that patient be taken to the laboratory at other than regularly scheduled hours or out of sequence so that
scheduled patients are delayed; ‡Worst lesion type (American College of Cardiology/American Heart Association Task Force
classification of lesion type) attempted during procedure; §Percentages are now percentages for year (e.g., 43.7% of coronary
angioplasties performed in 1996 used a stent).
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urgent procedure, receive a GP IIb/IIIa inhibitor, have a
recent MI, receive thrombolytic therapy, have unstable
angina and have complex lesion morphology.
Stent use increased from 44% in 1996 to 72% in 1998
(test for trend p , 0.001), and the proportion of stents that
were unplanned decreased from 44% to 14% (test for trend
p , 0.001). Individual hospitals varied widely in their use of
stents (from 28% of procedures to 93%; p , 0.001).
Although stent use was much more prevalent by 1998, there
was still a range of stent use among laboratories (29% to
95%).
The propensity score model revealed several independent
predictors of receiving a coronary stent (Table 2; Hosmer–
Lemeshow goodness-of-fit statistic p 5 0.7).
Outcomes. Overall, there were 76 deaths (0.5%) and 77
emergency CABG procedures (0.5%). Stents were associ-
ated with a significant reduction in both in-hospital mor-
tality and emergency CABG (Table 3). Stents had their
greatest effect on reducing “unstable” CABG procedures
(Table 3). All results were essentially unchanged after
adjustment for all other potential confounders (Table 3). Of
the 76 deaths, 60 (79%) occurred early (#24 h of the
procedure). There was a statistically significant reduction in
early mortality (0.3% in stent group vs. 0.5% in balloon
group, p 5 0.028) but not later (.24 h) mortality (0.1% in
both groups, p 5 0.1).
Among stent procedures, 8,410 (79%) were planned and
2,280 (21%) were unplanned. The mortality among planned
stenting (0.3%) was lower than among unplanned stenting
(0.7%, p 5 0.01). Excluding unplanned stents, the effect of
planned stenting alone versus balloon PCI was more pro-
nounced: multivariable OR for death, 0.33 (95% CI: 0.21,
0.50); for CABG, 0.33 (95% CI: 0.19, 0.58); and for any
death or CABG, 0.33 (95% CI: 0.22, 0.50).
The need for emergency CABG was associated with a
significant increase in mortality (7.8% vs. 0.4% in patients
not requiring emergency CABG; p , 0.001). In order to
assess the contribution of reduced CABG incidence to the
stent-mortality relationship, we determined the OR for
mortality from stenting after adjusting for the difference in
emergency CABG due to stents. If reduced CABG were
the sole reason for reduced mortality, this analysis would
produce an OR of 1. Although adjusting for emergency
CABG somewhat reduced the OR, stents still significantly
reduced the risk of death (multivariable OR 0.58; 95% CI:
0.36, 0.94). In addition, the beneficial effect of stents on
mortality was similar for patients undergoing emergency
CABG (multivariable OR 0.56) versus those not undergo-
Table 2. Variables in Propensity Score*
Clinical Characteristic
Multivariable
OR (95% CI) p Value
Age (10-year increments) 0.99 (0.96, 1.03) 0.70
Congestive heart failure 1.02 (0.85, 1.22) 0.86
Diabetes mellitus 0.83 (0.76, 0.91) , 0.001
Emergency procedure 0.002
Elective Reference
Urgent 0.90 (0.77, 1.04)
Emergency 0.78 (0.68, 0.90)
Female gender 0.87 (0.80, 0.93) , 0.001
Hypertension 0.93 (0.86, 1.00) 0.04
Glycoprotein IIb/IIIa receptor blocker 1.26 (1.13, 1.42) , 0.001
Laboratory (n 5 33) — , 0.001
MI within 24 h before PCI 0.71 (0.60, 0.84) , 0.001
MI 2–7 days before PCI 0.98 (0.87, 1.11) 0.77
MI 8–30 days before PCI 0.98 (0.74, 1.30) 0.91
Multivessel disease 0.86 (0.80, 0.93) , 0.001
PCI done during diagnostic procedure 0.95 (0.88, 1.03) 0.22
Peripheral vascular disease 0.88 (0.74, 1.04) 0.13
Prior CABG 0.72 (0.64, 0.81) , 0.001
Prior thrombolytic therapy 1.26 (1.03, 1.53) 0.02
Prior PCI 0.66 (0.61, 0.72) , 0.001
Renal insufficiency 0.97 (0.75, 1.25) 0.79
Shock 0.92 (0.69, 1.24) 0.60
Unstable angina 1.07 (0.98, 1.17) 0.11
Worst lesion type attempted 0.01
Type A Reference
Type B 1.14 (1.02, 1.28)
Type C 1.01 (0.89, 1.15)
Year , 0.001
1996 Reference
1997 2.02 (1.79, 2.27)
1998 3.57 (3.15, 4.06)
*Abbreviations and variable definitions as in Table 1.
Table 3. Effect of Stents on Outcomes*
Outcome
Number (%)
Unadjusted OR
(95% CI)
p-value
Adjusted OR
(95% CI)
p-value
Balloon Only
n 5 6,121
Stent
(Planned/Unplanned)
n 5 10,690
In-Hospital Mortality 39 (0.6%) 37 (0.3%) 0.54 (0.36, 0.81) 0.55 (0.34, 0.89)
P 5 0.003 P 5 0.014
Emergent CABG† 41 (0.7%) 36 (0.3%) 0.50 (0.32, 0.77) 0.47 (0.29, 0.76)
P 5 0.002 P 5 0.002
Stable 11 (0.2%) 9 (0.1%) 0.47 (0.20, 1.06) 0.54 (0.21, 1.35)
P 5 0.07 P 5 0.19
Unstable 30 (0.5%) 26 (0.2%) 0.49 (0.28, 0.86) 0.43 (0.23, 0.79)
P 5 0.014 P 5 0.007
In-Hospital Mortality or CABG 76 (1.2%) 71 (0.7%) 0.53 (0.39, 0.72) 0.51 (0.34, 0.77)
P , 0.001 P 5 0.001
*CABG 5 coronary artery bypass graft surgery; CI 5 confidence interval; n 5 number; OR 5 odds ratio; †defined in text.
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ing CABG (multivariable OR 0.59; test for interaction p 5
0.97).
There were no significant interactions between device
type and any of the a priori subgroups: age, diabetes, use of
GP IIb/IIIa receptor blockers, MI within 24 h prior to PCI
and lesion type (all p . 0.10). That is, the effect of stenting
on reducing mortality was statistically indistinguishable
between subgroups with and without these risk factors.
With respect to GP IIb/IIIa inhibitors, the p-value of the
test for interaction was 0.94 (i.e., stents had similar effects
on mortality relative to balloons in those receiving, vs. not
receiving, GP IIb/IIIa receptor blockers). In those receiving
GP IIb/IIIa inhibitors, the adjusted OR for stents versus
balloons was 0.57 (95% CI: 0.21, 1.56) and in those not
receiving GP IIb/IIIa inhibitors the adjusted OR was 0.60
(95% CI: 0.33, 1.08).
DISCUSSION
Overall findings. This study demonstrated a significantly
lower in-hospital mortality and emergency CABG risk with
the use of coronary stenting compared with balloon angio-
plasty. Overall, stents were associated with a 49% reduction
in the odds of death or CABG. This represents an absolute
risk reduction for mortality and CABG of 0.3% and 0.4%,
respectively. Although the absolute risk difference is small,
the potential benefit to the population requiring coronary
interventions could be great, given the tremendous number
of procedures performed worldwide.
Prior studies. Randomized trials of stenting in the absence
of platelet GP IIb/IIIa receptor blockade have been too
small to exclude an independent effect of stents (positive or
negative) on mortality (2–5,23). Some studies had more
cardiac events in the stent group (3,4,6) and therefore some
have argued that stenting, in the absence of GP IIb/IIIa
receptor blockade, may actually increase risk (1). However,
a recent observational study using administrative data from
California demonstrated a significant reduction in in-
hospital mortality in patients receiving stents compared with
those not receiving stents (8). This study did not account for
multiple potential confounders simultaneously, nor did it
account for the effects of clustering. Clustering (or correla-
tion of outcomes within centers) can lead to biased variance
estimates and thus biased study inference (17). In addition,
administrative data lack clinical, angiographic, medication
(e.g., GP IIb/IIIa inhibitor use) and other device (e.g.,
atherectomy) information, making it impossible to adjust
for potential differences between stented and nonstented
patients on these factors. Despite these potential limita-
tions, the finding of an approximately 50% reduction in
in-hospital death in this prior study is consistent with our
results.
Our study also suggests that stents themselves indepen-
dently reduce periprocedural mortality relative to balloon
angioplasty. Although the EPISTENT study demonstrated
a reduction in six-month mortality using stents plus abcix-
imab compared with balloons plus abciximab (10), the
mechanism of this finding was not elucidated. A reduction
in MI from stents did not appear to explain the findings
(10). The relative contribution of stenting to periprocedural
versus later mortality reduction also was not determined.
Finally, the mortality benefit from stenting could have relied
entirely on coadministration of abciximab. Our data now
support a mortality benefit from stenting itself and suggest
that at least some of the intermediate-term benefit from
stenting derives from periprocedural mortality reduction.
The mortality benefit of stenting relative to balloon angio-
plasty also appears to be the same for procedures that use
GP IIb/IIIa inhibitors (i.e., stents with GP IIb/IIIa inhib-
itors vs. balloons with GP IIb/IIIa inhibitors) and those that
do not (i.e., stents without GP IIb/IIIa inhibitors vs.
balloons without GP IIb/IIIa inhibitors), although these
analyses had limited power.
Study limitations. There are several important potential
limitations inherent in any observational study. First, al-
though it is possible that the mortality benefit was a chance
finding, the consistency of benefit in different subgroups and
the supportive data from California (8) suggest that these
findings were not due to chance.
Second, stents could appear beneficial if they were used in
lieu of balloons by lower risk individuals or by lower risk
hospitals. However, extensive multivariable analyses that
adjusted for numerous clinical and angiographic variables
and for individual laboratories did not alter the magnitude
of effect of stenting, suggesting that uncontrolled confound-
ing did not produce these results. In addition, we included
“unplanned” stents in the stent group to insure that the stent
group included patients who had unsatisfactory results from
balloon angioplasty. This inclusion also eliminated the
possibility that operators who planned to use a stent
miscoded it as “unplanned” only because predilation with
the balloon did not produce adequate results. The fact that
the percentage of stent procedures that were planned (79%)
was almost identical to that found in the New Approaches
to Coronary Interventions registry (82%) (24) suggests that
substantial miscoding was unlikely. Regardless, a mortality
benefit from stenting persisted despite the inclusion of
unplanned procedures, which are associated with an in-
creased risk of complications (24). Finally, although uncon-
trolled confounding is still possible (e.g., due to lesion
complexity not captured by the lesion type variable), it is
extremely unlikely to have produced the observed results.
For example, an unmeasured confounder present in 50% of
the population would have to be associated with a 25-fold
increased risk of both stent use and mortality to have
produced our results (25). We know of no such risk factor.
Third, the study could only address the effect of stents
versus balloons when platelet GP IIb/IIIa blockers were
used concomitantly with both devices and, separately, for
stents versus balloons when IIb/IIIa blockers were not used.
The study did not and could not address the effect of adding
a platelet GP IIb/IIIa blocker to stent procedures (vs. stents
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without GP IIb/IIIa blockade) because of confounding by
indication (platelet GP IIb/IIIa receptor blockers are used in
higher risk individuals). The study does not, therefore,
contradict the findings of EPISTENT (10). Rather, the
lack of a significant interaction by GP IIb/IIIa receptor
blockade suggests that stents may reduce mortality relative
to balloon procedures when IIb/IIIa blockers are used with
both types of devices and also may reduce mortality relative
to balloon procedures when IIb/IIIa blockers are not used
with both.
Fourth, registry data such as ours are not subject to strict
quality assurance measures, making misclassification possi-
ble, albeit unlikely to alter the study conclusions.
Fifth, we could not examine MI outcomes or cause of
death in our study. However, the difference in mortality by
device type appeared to be due to differences in early
mortality, suggesting that reductions in early complications
of PCI from stents could explain our findings.
Conclusions. This study provides evidence that coronary
stenting reduces the risk of periprocedural mortality com-
pared with balloon angioplasty. This early reduction in
mortality provides one possible explanation for the six-
month mortality benefit seen in EPISTENT (10) and
extends these findings to broad-based PCI practice. The
results also add to recent administrative data analyses (8) by
demonstrating a reduction in mortality from stents that is
independent of case-mix, angiographic lesion characteristic,
and individual laboratories. The mortality benefit from
stents relative to balloon procedures provides additional
justification for the addition of coronary stenting to percu-
taneous coronary interventional procedures, both those that
use and do not use platelet GP IIb/IIIa blockade.
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